Galectin-3 (Gal-3) is a proinflammatory and profibrotic protein especially overexpressed after Acute Kidney Injury (AKI). The early renal prognostic value of Gal-3 after AKI in critically ill patients remains unexplored. The objective was to evaluate the prognostic value of plasma level of Gal-3 for Major Adverse Kidney Events (MAKE) and mortality 30 days after ICU admission across AKI stages. This is an ancillary study of a prospective, observational, multicenter cohort (FROG-ICU). AKI was defined using KDIGO definition. Two thousand and seventy-six patients had a Gal-3 plasma level measurement at ICU admission. Seven hundred and twenty-three (34.8%) were females and the median age was 63 [51, 74] years. Eight hundred and seven (38.9%) patients developed MAKE, 774 (37.3%) had AKI and mortality rate at 30 days was 22.4% (N = 465). Patients who developed MAKE had higher Gal-3 level at admission compared to patients without (30.2 [20.8, 49.2] ng/ml versus 16.9 [12.7, 24.3] ng/ml, p < 0.001, respectively. The area under the receiver operating characteristic curve of Gal-3 to predict MAKE was 0.76 CI95% [0.74–0.78], p < 0.001. Gal-3 was associated with MAKE (OR 1.80 CI95% [1.68–1.93], p < 0.001, non-adjusted and OR 1.37 CI95% [1.27–1.49], p < 0.001, adjusted). The use of Gal-3 improved prediction performance of prediction model including SAPSII, Screatadm, pNGAL with a NRI of 0.27 CI95%(0.16–0.38), p < 0.001. Median Gal-3 was higher in non-survivors than in survivors at 30 days (29.2 [20.2, 49.2] ng/ml versus 18.8 [13.3, 29.2] ng/ml, p < 0.001, respectively). Plasma levels of Gal-3 were strongly associated with renal function, with an increased risk of MAKE and death after ICU admission. Trial registration ClinicalTrials.gov NCT01367093. Registered on 6 June 2011.

中文翻译：

---

血浆 Galectin-3 升高与 ICU 入院后的主要肾脏不良事件和死亡有关

Galectin-3 (Gal-3) 是一种促炎和促纤维化蛋白，特别是在急性肾损伤 (AKI) 后过度表达。危重患者 AKI 后 Gal-3 的早期肾脏预后价值仍未探索。目的是评估血浆 Gal-3 水平对主要不良肾脏事件 (MAKE) 和 ICU 入院 30 天后跨 AKI 阶段死亡率的预后价值。这是一项前瞻性、观察性、多中心队列（FROG-ICU）的辅助研究。AKI 是使用 KDIGO 定义的。2076 名患者在 ICU 入院时进行了 Gal-3 血浆水平测量。723 名 (34.8%) 为女性，中位年龄为 63 [51, 74] 岁。807 名 (38.9%) 患者发生 MAKE，774 名 (37.3%) 发生 AKI，30 天死亡率为 22.4% (N = 465)。ICU入院后MAKE和死亡的风险增加。试验注册 ClinicalTrials.gov NCT01367093。于 2011 年 6 月 6 日注册。